1. HBW Insight
  2. >>Geography
  3. >>International

Abbott Stops Using ‘#1 Infant Formula Brand’ Claim After Finding Supporting Data Out Of Date

Claiming Top Brand Among Formulas In US Remains Contentious Advertising Issue

 
• By Malcolm Spicer

Mead Johnson not only gains with Abbott stopping use of claim on Similac packaging, but also continues using similar claim on Enfamil packages, “#1 Pediatrician Recommended Brand.”  In NAD report, Abbott says data backing up its claim apparently wasn’t current.

Mead Johnson continues using a claim of “#1 recommended brand” variety on its Enfamil formula line, left, while Abbott is voluntarily removing a similar claim from its Similac line, right. • Source: Shutterstock/HBW Insight

A competitor’s challenge to Abbott’s “#1 infant formula brand” label claim for Similac infant formula products was resolved much faster as well as more simply than Abbott’s problems linked to bacterial contamination at its largest US formula plant.

The competitor, Enfamil formula marketer Mead Johnson & Co. LLC, could say having an advertising challenge reviewed by BBB National Programs Inc. National Advertising Division attorneys was simpler and faster...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By David Ridley

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By David Ridley

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.

Stada Expands Oilatum Range To Meet Saudi Arabia’s Skin-Care Needs

 
• By David Ridley

Stada launches nine new Oilatum products in Saudi Arabia including “rich moisturising creams for intense hydration, gentle body washes for daily cleansing, and baby-specific products like soothing bath bubbles and head-to-toe wash.”

Bayer And GSCF Paper Outlines ‘Practical Actions’ For Scaling Self-Care Globally

 
• By David Ridley

Bayer Consumer Health, the Global Self-Care Federation and the Business Council for International Understanding outline in a paper how industry can work with multilateral organizations, governments, financial institutions, and stakeholders to "recognize and champion self-care as a fundamental driver of global health progress."

More from Geography

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

EU Parliament Calls For Review Of Wastewater Directive’s Impact On Pharma Sector

 
• By David Ridley

At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By David Ridley

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.